Merck has announced plans to acquire Cidara Therapeutics for $9.2 billion, or $221.50 per share. Representing a heavy premium to the biotech's prior trading price, the bid caused its shares to surge.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results